"Is it time for personalised medicine for Ameloblastoma?": A hypothesis.

Narayan, Bhaskar; Kumar, Somesh; Kumar, Priya; Urs, Aadithya B

Narayan, Bhaskar; Kumar, Somesh; Kumar, Priya; Urs, Aadithya B.

Afiliación

Narayan B; Department of Oral and Maxillofacial Pathology and Microbiology, Maulana Azad Institute of Dental Sciences, New Delhi, Delhi, India.
Kumar S; Department of Pediatrics, Maulana Azad Medical College, New Delhi, Delhi, India.
Kumar P; Department of Oral and Maxillofacial Pathology and Microbiology, Maulana Azad Institute of Dental Sciences, New Delhi, Delhi, India.
Urs AB; Department of Oral and Maxillofacial Pathology and Microbiology, Maulana Azad Institute of Dental Sciences, New Delhi, Delhi, India.

J Oral Maxillofac Pathol ; 27(4): 744-745, 2023.

Article en En | MEDLINE | ID: mdl-38304511

ABSTRACT

ABSTRACT

Ameloblastoma is a benign odontogenic tumor that is locally destructive. The most common treatment option is surgery, which often results in disfigurement of the face. BRAFV600E is the common gene mutation associated with its pathogenesis. Therefore, this paper hypothesizes the use of targeted drug therapy against this mutated gene.

Palabras clave

Ameloblastoma; BRAFV600E; targeted medicine

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: J Oral Maxillofac Pathol Año: 2023 Tipo del documento: Article País de afiliación: India Pais de publicación: India

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google